Parenteral Drugs (India) Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 14.42 million compared to INR 20.37 million a year ago. Revenue was INR 14.53 million compared to INR 20.49 million a year ago. Net loss was INR 345.25 million compared to INR 309.75 million a year ago. Basic loss per share from continuing operations was INR 11.58 compared to INR 10.41 a year ago. Diluted loss per share from continuing operations was INR 11.58 compared to INR 10.41 a year ago. Basic loss per share was INR 11.58 compared to INR 10.41 a year ago. Diluted loss per share was INR 11.58 compared to INR 10.41 a year ago.
For the nine months, sales was INR 67.23 million compared to INR 95.98 million a year ago. Revenue was INR 67.56 million compared to INR 96.35 million a year ago. Net loss was INR 1,001.75 million compared to INR 968.68 million a year ago. Basic loss per share from continuing operations was INR 33.59 compared to INR 32.55 a year ago. Diluted loss per share from continuing operations was INR 33.59 compared to INR 32.55 a year ago. Basic loss per share was INR 33.59 compared to INR 32.55 a year ago. Diluted loss per share was INR 33.59 compared to INR 32.55 a year ago.